The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 38 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Cholesterol, LDL  [Clear All Filters]
2022
Anagnostis, P., Florentin M., Livadas S., Lambrinoudaki I., & Goulis D. G. (2022).  Bone Health in Patients with Dyslipidemias: An Underestimated Aspect.. Int J Mol Sci. 23(3), 
2020
Ferro, C. J., Sarafidis P., & Ortiz A. (2020).  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.. N Engl J Med. 382(21), e65.
2019
Colijn, J. M., Hollander A. I. den, Demirkan A., Cougnard-Grégoire A., Verzijden T., Kersten E., et al. (2019).  Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia.. Ophthalmology. 126(3), 393-406.
Anagnostis, P., Vaitsi K., Veneti S., Georgiou T., Paschou S. A., Lambrinoudaki I., et al. (2019).  Management of dyslipidaemias in the elderly population-A narrative review.. Maturitas. 124, 93-99.
Boulmpou, A., Kartas A., Farmakis I., Zafeiropoulos S., Nevras V., Papadimitriou I., et al. (2019).  Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design.. Hellenic J Cardiol. 60(4), 249-253.
2017
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Gencer, B., Koskinas K. C., Räber L., Karagiannis A., Nanchen D., Auer R., et al. (2017).  Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.. J Am Heart Assoc. 6(11), 
Polychronopoulos, G., & Tziomalos K. (2017).  Novel treatment options for the management of heterozygous familial hypercholesterolemia.. Expert Rev Clin Pharmacol. 10(12), 1375-1381.
Tziomalos, K., Giampatzis V., Bouziana S. D., Spanou M., Kostaki S., Papadopoulou M., et al. (2017).  Prognostic significance of major lipids in patients with acute ischemic stroke.. Metab Brain Dis. 32(2), 395-400.
Tziomalos, K. (2017).  The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.. Curr Pharm Des. 23(10), 1495-1499.
2016
Anagnostis, P., Karras S., Lambrinoudaki I., Stevenson J. C., & Goulis D. G. (2016).  Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.. Int J Clin Pract. 70(12), 967-977.
Tziomalos, K. (2016).  Unresolved issues in lipid-lowering treatment.. Panminerva Med. 58(2), 191-5.
2015
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.. J Diabetes Complications. 29(1), 142-5.
2014
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Achieving lipid targets in primary care settings.. Curr Med Res Opin. 30(10), 1971-4.
Tziomalos, K., Karagiannis A., & Athyros V. G. (2014).  Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.. Curr Pharm Des. 20(40), 6306-13.
2013
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
2012
Kadoglou, N. P. E., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., Kostakis A., et al. (2012).  Adipokines: a novel link between adiposity and carotid plaque vulnerability.. Eur J Clin Invest. 42(12), 1278-86.
2011
Kourtis, A., Gkiomisi A., Mouzaki M., Makedou K., Anastasilakis A. D., Toulis K. A., et al. (2011).  Apelin levels in normal pregnancy.. Clin Endocrinol (Oxf). 75(3), 367-71.
Athyros, V. G., Karagiannis A., Ganotakis E. S., Paletas K., Nicolaou V., Bacharoudis G., et al. (2011).  Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.. Curr Med Res Opin. 27(8), 1659-68.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Peletidou A., Vosikis C., et al. (2011).  Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors.. Nutr Metab Cardiovasc Dis. 21(3), 213-21.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.. Int Angiol. 30(3), 295; author reply 296.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Ezetimibe and low density lipoprotein subfractions: an ongoing debate.. Curr Med Res Opin. 27(3), 693-5.
Makedou, K., Kourtis A., Gkiomisi A., Toulis K. A., Mouzaki M., Anastasilakis A. D., et al. (2011).  Oxidized low-density lipoprotein and adiponectin levels in pregnancy.. Gynecol Endocrinol. 27(12), 1070-3.
2010
Kadoglou, N. P. E., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., & Liapis C. D. (2010).  Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.. J Vasc Surg. 51(1), 114-21.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.